A5085341141- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Inhalation and Respiratory Drug Delivery
- Peptidase Inhibition and Analysis
- Electrolyte and hormonal disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Biosimilars and Bioanalytical Methods
- Nausea and vomiting management
- Erythropoietin and Anemia Treatment
- Effects of Radiation Exposure
- Innovation Policy and R&D
- Patient-Provider Communication in Healthcare
- Healthcare Systems and Technology
- Occupational and environmental lung diseases
National Archaeological Museum
2017
Azienda Ospedaliera San Camillo-Forlanini
1999-2015
Carlo Forlanini Hospital
1989-2010
IRCCS San Camillo Hospital
2007
AstraZeneca (Italy)
2004
Ca' Foncello Hospital
2004
Bristol-Myers Squibb (Italy)
2003
Azienda Sanitaria Unità Locale di Reggio Emilia
2003
Mario Negri Institute for Pharmacological Research
2003
Nini Hospital
1999
PURPOSE: To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, (MIC) chemotherapy in patients stage IIIB (limited to T4 for pleural effusion N3 supraclavicular lymph nodes) or IV non–small-cell lung cancer (NSCLC). The end points were the evaluation of quality life (QoL), response rates, survival, toxicity. PATIENTS AND METHODS: Three hundred seven randomized receive either 1,000 mg/m 2 on days 1, 8, 15 plus 100 day 2, every 28 days, mitomycin 6 , ifosfamide 3,000 mesna 1...
Two hundred sixteen patients with unresectable non-small cell lung carcinoma were randomly allocated to receive etoposide (120 mg/m2, days 1–3) either alone or in combination high-dose cisplatin (60 1–2). The patients' distribution and characteristics similar the two treatment arms. objective response rate for was 7% versus 25.8% plus (P < 0.005). Median progression-free survival arm 3.5 months 5 = 0.43). median time 6 compared 8 combined 0.87). Significantly more nausea/vomiting 0.005),...
Abstract BACKGROUND The objective of the current study was to define activity and tolerability, as well influence on resectability, combination gemcitabine, paclitaxel, cisplatin (GTP) induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carcinoma (NSCLC). METHODS Forty‐nine chemotherapy‐naïve (median age, 61 years; World Health Organization performance status, 0–1) biopsy‐proven disease received 1000 mg/m 2 125 50 Days 1 8 every 3 weeks until reevaluation surgery or...
Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The aim this observational multicenter study was to analyze medical and economic implications SIADH setting. This included 90 oncological from 28 Italian institutions that developed between January 2010 September 2015. Data on clinical-pathological characteristics, anticancer therapies, hyponatremia, related treatments were statistically analyzed. majority lung (73%) with...
Aims To evaluate the efficacy and treatment compliance in elderly patients with advanced non-small cell lung cancer (NSCLC) of two chemotherapeutic agents mild toxicity, 153 previously untreated aged over 70 years were randomized to receive lonidamine (450 mg daily p.o. until progression), vindesine (3 mg/m 2 /daily i.v. weekly for 4 weeks then every combination drugs at same dose schedule, or supportive therapy only a four-arm factorial trial. Methods 126 included final analysis. Their...
Objective: To evaluate toxicity and patterns of radiologic lung injury on CT images after hypofractionated image-guided stereotactic body radiotherapy (SBRT) delivered with helical tomotherapy (HT) in medically early stage inoperable non-small-cell cancer (NSCLC). Methods: 28 elderly patients (31 lesions) compromised pulmonary reserve were deemed enrolled to undergo SBRT. Patterns based appearance assessed at baseline during follow up. Acute (6 months or less) late (more than 6 months)...
Malignant pleural mesothelioma represents a rare disease, for which chemotherapy actually remains unsatisfactory. From August 1998 to November 2001, 28 chemo-radio-immunonaive patients were consecutively enrolled in the trial: 22/6 males/females; median age 63 years (range, 45-79); ECOG PS 1 0-2). They treated with epirubicin (100 mg/m 2 iv on day 1) plus gemcitabine (1000 days and 8) every 4 weeks 6 cycles. Patients who responded (n = 6) subsequently interleukin-2 (4,500,000 IU)...
The objective of the present study was to evaluate activity and toxicity an original combination paclitaxel (Taxol), ifosfamide, carboplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC). Sixty-one previously untreated NSCLC were enrolled by five institutions. Paclitaxel given at dose 200 mg/m2 iv 3 hours, ifosfamide (with mesna) g/m2 area under curve 5, on day 1, every 21 days for a total six cycles responding or stabilized patients. Among 59 evaluable response, 2...
Serum levels of carcinoembryonic antigen (CEA), squamous cell carcinoma (SCC) and immunosuppressive acidic protein (IAP) were measured in 37patients with lung cancers, 24 non-cancer pulmonary diseases normal controls. We evaluated the sensitivity, specificity accuracy these three markers alone combined. The highest was observed for SCC (83.3%) sensitivity IAP (94.6%). best obtained combined determination CEA SCC. In cancer correlation between (r=0.30 r=0.45 diseases). Although test is not...
8265 Background: Lung cancer is extremely common and its cost for society not extensively studied. ALCEA (Advanced Cancer Economic Assessment) -an observational cost-of-illness study -has generated economic data on patients affected by NSCLC in an advanced stage, exploring both direct indirect costs determined this pathology Italy. Methods: A total of 189 treated with first line chemotherapy (1st L), second (2nd L) or supportive therapy (ST) were observed a six-month period until death....
Aim and background The aim of this Phase II trial was to verify the therapeutic activity tolerability chemotherapy with lonidamine (LND) plus cyclophosphamide (CTX) in advanced non-small cell lung cancer (NSCLC) elderly. rationale combination is reported. CTX showed mild toxicity, a 12% objective response (OR) monochemotherapy; LND potentiated vitro antiproliferative alkylating agents, mainly CTX, without increasing myelotoxicity, particularly important Methods schedule consisted 600 mg/m 2...
8265